CMPS logo

CMPS
COMPASS Pathways

7,673
Mkt Cap
$504.01M
Volume
578,469.00
52W High
$7.09
52W Low
$2.25
PE Ratio
-1.96
CMPS Fundamentals
Price
$5.35
Prev Close
$5.25
Open
$5.53
50D MA
$5.89
Beta
1.38
Avg. Volume
1.56M
EPS (Annual)
-$2.30
P/B
13.41
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Compass Pathways to Participate in Two Investor Conferences in December
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate...
Business Wire·8h ago
News Placeholder
More News
News Placeholder
COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Given Consensus Recommendation of "Moderate Buy" by Analysts
Shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine research firms that are presently covering the stock...
MarketBeat·10d ago
News Placeholder
FY2026 EPS Estimates for CMPS Decreased by Cantor Fitzgerald
COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) - Investment analysts at Cantor Fitzgerald decreased their FY2026 earnings estimates for COMPASS Pathways in a research note issued to...
MarketBeat·12d ago
News Placeholder
What is HC Wainwright's Estimate for CMPS FY2025 Earnings?
COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) - Research analysts at HC Wainwright boosted their FY2025 earnings estimates for shares of COMPASS Pathways in a research report issued...
MarketBeat·12d ago
News Placeholder
COMPASS Pathways (NASDAQ:CMPS) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS
COMPASS Pathways (NASDAQ:CMPS - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus...
MarketBeat·14d ago
News Placeholder
COMPASS Pathways (NASDAQ:CMPS) Price Target Raised to $11.00
Morgan Stanley boosted their target price on shares of COMPASS Pathways from $10.00 to $11.00 and gave the stock an "overweight" rating in a research report on Wednesday...
MarketBeat·14d ago
News Placeholder
COMPASS Pathways (NASDAQ:CMPS) Stock Price Down 9.8% - Here's What Happened
COMPASS Pathways (NASDAQ:CMPS) Shares Down 9.8% - What's Next...
MarketBeat·14d ago
News Placeholder
Compass Pathways to Participate in Stifel 2025 Healthcare Conference
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate...
Business Wire·15d ago
News Placeholder
Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third...
Business Wire·16d ago
News Placeholder
NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression
NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision...
PR Newswire·21d ago

Latest CMPS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.